Articles Induction therapy with the selective interleukin23 inhibitor risankizumab in patients with moderatetosevere Crohn's disease a randomised doubleblind placebocontrolled phase 2 study

In this shortterm study risankizumab was more effective than placebo for inducing clinical remission in patients with active Crohn's disease. Therefore selective blockade of interleukin23 via inhibition of p19 might be a viable therapeutic approach in Croh...